Prothena | PRTA - Sales Revenues


Prothena reported $2.42M in Sales Revenues for its fiscal quarter ending in September of 2025.





Sales Change Date
Acadia Pharmaceuticals USD 284M 5.4M Dec/2025
Agios Pharmaceuticals USD 19.97M 7.07M Dec/2025
Akebia Therapeutics USD 57.34M 10.84M Mar/2025
ALKERMES USD 384.5M 9.7M Dec/2025
Alnylam Pharmaceuticals USD 1.1B 150M Dec/2025
Amgen USD 9.9B 340M Dec/2025
Biogen USD 2.28B 250M Dec/2025
BioMarin Pharmaceutical USD 875M 99M Dec/2025
Exelixis USD 598.66M 860K Dec/2025
Incyte USD 1.51B 140M Dec/2025
Ionis Pharmaceuticals USD 203M 46M Dec/2025
MacroGenics USD 72.84M 50.6M Sep/2025
Nektar Therapeutics USD 24.12M 635K Sep/2024
Neurocrine Biosciences USD 805.5M 10.6M Dec/2025
Prothena USD 2.42M 2M Sep/2025
Regeneron Pharmaceuticals USD 3.88B 130M Dec/2025
Ultragenyx Pharmaceutical USD 207M 47M Dec/2025
Vertex Pharmaceuticals USD 3.19B 110M Dec/2025
Xoma USD 25K 5M Sep/2024